

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SUNWAH KINGSWAY
新華滙富

SUNWAH KINGSWAY CAPITAL HOLDINGS LIMITED

新華滙富金融控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00188)

ANNOUNCEMENT PURSUANT TO

RULES 13.51B(2) AND 13.51(2)(n)(iv) OF THE LISTING RULES

This announcement is made by the board (the “**Board**”) of directors (the “**Director(s)**”) of Sunwah Kingsway Capital Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.51B(2) and 13.51(2)(n)(iv) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to the Statement of Disciplinary Action (the “**Statement**”) issued by the Stock Exchange on 18 July 2022 in relation to the Stock Exchange’s disciplinary action against Enterprise Development Holdings Limited (a company listed on the Main Board of the Stock Exchange (stock code: 1808)) (“**Enterprise Development**”) and one of its former executive directors (the “**Enterprise Development ED**”). Neither Enterprise Development nor the Enterprise Development ED was or is, at any relevant time, associated with, or a director of, the Group. Capitalised terms used herein, unless otherwise defined, shall have the same meanings as those defined in the Statement.

According to the Statement, the Stock Exchange censured Enterprise Development and the Enterprise Development ED, and in addition, imposed a prejudice to investors’ interests statement against the Enterprise Development ED. The Listing Committee found that (1) Enterprise Development breached Rule 2.13(2) by publishing inaccurate, incorrect and/or misleading information about the Enterprise Development ED in the Appointment Announcement and the Notice of AGM, and (2) the Enterprise Development ED breached her duties under Rule 3.08 and her Undertaking by (a) providing inaccurate, incorrect and/or misleading information to Enterprise Development in respect of her biographical details, and (b) failing to procure Enterprise Development’s compliance with Rule 2.13(2) in respect of the Appointment Announcement and the Notice of AGM.

As stated in the Statement, the sanctions and directions apply only to Enterprise Development and the Enterprise Development ED, and not to any other past or present members of the board of directors of Enterprise Development. For further details of the disciplinary action, please refer to the Statement issued by the Stock Exchange at https://www.hkex.com.hk/-/media/HKEX-Market/Listing/Rules-and-Guidance/Disciplinary-and-Enforcement/Disciplinary-Sanctions/2022/220718_SoDA.pdf.

Dr. Guan Huanfei (“**Dr. Guan**”), an independent non-executive Director and a member of the audit committee, nomination committee, compensation committee and corporate governance committee of the Company, was an executive director of Enterprise Development at the relevant time of the Appointment Announcement. He resigned from the board of directors of Enterprise Development in May 2021.

The Board has considered the Statement and the information set out therein. In view of the facts that (i) the subject matter of the Statement does not in any way relate to the affairs of the Group; (ii) it will not have any material impact on the business operations and financial position of the Group; and (iii) there is no evidence casting doubt upon Dr. Guan’s suitability as an independent non-executive director, the Board considers that the continuous holding of office by Dr. Guan as an independent non-executive Director is appropriate.

Save as disclosed in the Statement and this announcement, there is no other information relating to Dr. Guan that is required to be disclosed pursuant to Rules 13.51B(2) and 13.51(2)(h) to (v) of the Listing Rules and there is no other matter in relation to Dr. Guan’s directorship in the Company that needs to be brought to the attention of the shareholders of the Company.

By Order of the Board
Sunwah Kingsway Capital Holdings Limited
Vincent Wai Shun Lai
Company Secretary

Hong Kong, 28 July 2022

As at the date of this announcement, the directors of the Company are Jonathan Koon Shum Choi as Chairman, Michael Koon Ming Choi as Chief Executive Officer & Executive Director, Janice Wing Kum Kwan and Lee G. Lam as Non-Executive Directors, Robert Tsai To Sze, Elizabeth Law and Huanfei Guan as Independent Non-Executive Directors.